Zongertinib to Target HER2-Driven Resistance in EGFR Mutation-Positive NSCLC: A Case Report.
- DOI
- 10.1016/j.cllc.2026.08.010
- Published
- 2026 Aug 23
- Container
- Clinical lung cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.cllc.2026.08.010,
title = {Zongertinib to Target HER2-Driven Resistance in EGFR Mutation-Positive NSCLC: A Case Report.},
author = {Torres-Jiménez J and Serrano-Gómez C and Baena-Espinar J and de Cabo HB and Zurera-Berjaga M and López-Martín A and Ponce-Aix S and Paz-Ares L and Zugazagoitia J},
year = {2026},
journal = {Clinical lung cancer},
doi = {10.1016/j.cllc.2026.08.010},
url = {https://doi.org/10.1016/j.cllc.2026.08.010}
}RIS
TY - JOUR TI - Zongertinib to Target HER2-Driven Resistance in EGFR Mutation-Positive NSCLC: A Case Report. AU - Torres-Jiménez J AU - Serrano-Gómez C AU - Baena-Espinar J AU - de Cabo HB AU - Zurera-Berjaga M AU - López-Martín A AU - Ponce-Aix S AU - Paz-Ares L AU - Zugazagoitia J PY - 2026 JO - Clinical lung cancer DO - 10.1016/j.cllc.2026.08.010 UR - https://doi.org/10.1016/j.cllc.2026.08.010 ER -
APA
J, T., C, S., J, B., HB, D. C., M, Z., A, L., S, P., L, P., & J, Z. (2026). Zongertinib to Target HER2-Driven Resistance in EGFR Mutation-Positive NSCLC: A Case Report.. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2026.08.010
Source records
- pubmed · retrieved 2026-09-25T01:06:29.999Z